Pharmacological inhibition of type i interferon signaling protects mice against lethal sepsis

Journal of Infectious Diseases

Volumn 209, Issue 6, 2014, Pages 960-970

  Dejager, Lien ^a   Vandevyver, Sofie ^a   Ballegeer, Marlies ^a   Van Wonterghem, Elien ^a   An, Ling Ling ^b   Riggs, Jeffrey ^b   Kolbeck, Roland ^b   Libert, Claude ^a  

^a GHENT UNIVERSITY   (Belgium)

^b MEDIMMUNE   (United States)

Author keywords

cecal ligation and puncture; endotoxemia; neutrophils; sepsis; type I interferons

Indexed keywords

BETA INTERFERON; CEFTRIAXONE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON RECEPTOR; INTERLEUKIN 12P70; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; METRONIDAZOLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAR1 5A3; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTOXEMIA; FEMALE; GENE EXPRESSION; HOST RESISTANCE; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; LEUKOCYTE; MALE; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SURVIVAL RATE;

CECAL LIGATION AND PUNCTURE; ENDOTOXEMIA; NEUTROPHILS; SEPSIS; TYPE I INTERFERONS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; BACTEREMIA; CECUM; ENDOTOXEMIA; FEMALE; HUMANS; INTERFERON TYPE I; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION;

EID: 84895769408     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit600     Document Type: Article

References (49)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10.
2. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9:517-24.
3. Dejager L, Pinheiro I, Dejonckheere E, Libert C. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol 2011; 19:198-208.
4. Pestka S, Krause CD,Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202:8-32.
5. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264:1918-21.
6. Lindenmann J, Burke DC, Isaacs A. Studies on the production, mode of action and properties of interferon. Br J Exp Pathol 1957; 38:551-62.
7. Auerbuch V, Brockstedt DG, Meyer-Morse N, O'Riordan M, Portnoy DA. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 2004; 200:527-33.
8. Weighardt H, Kaiser-Moore S, Schlautkotter S, et al. Type I IFN modulates host defense and late hyperinflammation in septic peritonitis. J Immunol 2006; 177:5623-30.
9. Mancuso G, Midiri A, Biondo C, et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J Immunol 2007; 178:3126-33.
10. Karaghiosoff M, Steinborn R, Kovarik P, et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 2003; 4:471-7.
11. Hwang SY, Hertzog PJ, Holland KA, et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc Natl Acad Sci U S A 1995; 92:11284-8.
12. Mahieu T, Park JM, Revets H, et al. The wild-derived inbred mouse strain SPRET/Ei is resistant to LPS and defective in IFN-beta production. Proc Natl Acad Sci U S A 2006; 103:2292-7.
13. Mahieu T, Libert C. Should we inhibit type I interferons in sepsis? Infect Immun 2007; 75:22-9.
14. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12:125-35.
15. Kelly-Scumpia KM, Scumpia PO, Delano MJ, et al. Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10. J Exp Med 2010; 207:319-26.
16. Sheehan KC, Lai KS, Dunn GP, et al. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 2006; 26:804-19.
17. Craciun FL, Schuller ER, Remick DG. Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival. J Immunol 2010; 185:6930-8.
18. Rathinam VA, Vanaja SK, Waggoner L, et al. TRIF licenses caspase-11- dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 2012; 150:606-19.
19. Honda K, Yanai H, Takaoka A, Taniguchi T. Regulation of the type I IFN induction: a current view. Int Immunol 2005; 17:1367-78.
20. Phipps-Yonas H, Seto J, Sealfon SC, Moran TM, Fernandez-Sesma A. Interferon-beta pretreatment of conventional and plasmacytoid human dendritic cells enhances their activation by influenza virus. PLoS Pathog 2008; 4:e1000193.
21. Huys L, Van Hauwermeiren F, Dejager L, et al. Type I interferon drives tumor necrosis factor-induced lethal shock. J ExpMed 2009; 206:1873-82.
22. Zhai Y, Qiao B, Gao F, et al. Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion. Hepatology 2008; 47:199-206.
23. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005; 4:854-65.
24. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin- 6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17:463-7.
25. Newcomb D, Bolgos G, Green L, Remick DG. Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock 1998; 10:110-7.
26. Qiu P, Cui X, Barochia A, Li Y, Natanson C, Eichacker PQ. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Investig Drugs 2011; 20:1555-64.
27. De Maio A, Torres MB, Reeves RH. Genetic determinants influencing the response to injury, inflammation, and sepsis. Shock 2005; 23:11-7.
28. Song M, Kellum JA. Interleukin-6. Crit Care Med 2005; 33:S463-5.
29. Vianna RC, Gomes RN, Bozza FA, et al. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 2004; 21:115-20.
30. Holzheimer RG. The significance of endotoxin release in experimental and clinical sepsis in surgical patients-evidence for antibiotic-induced endotoxin release? Infection 1998; 26:77-84.
31. Teijaro JR, Ng C, Lee AM, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013; 340:207-11.
32. Wilson EB, Yamada DH, Elsaesser H, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013; 340:202-7.
33. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6:164-70.
34. Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203:1637-42.
35. Flierl MA, Rittirsch D, Gao H, et al. Adverse functions of IL-17A in experimental sepsis. Faseb J 2008; 22:2198-205.
36. Osuchowski MF, Connett J,Welch K, Granger J, Remick DG. Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit Care Med 2009; 37:1567-73.
37. Alves-Filho JC, de Freitas A, Spiller F, Souto FO, Cunha FQ. The role of neutrophils in severe sepsis. Shock 2008; 30(Suppl 1):3-9.
38. Ishii M, Asano K, Namkoong H, et al. CRTH2 is a critical regulator of neutrophil migration and resistance to polymicrobial sepsis. J Immunol 2012; 188:5655-64.
39. Xin L, Vargas-Inchaustegui DA, Raimer SS, et al. Type I IFN receptor regulates neutrophil functions and innate immunity to Leishmania parasites. J Immunol 2010; 184:7047-56.
40. Brzoza-Lewis KL, Jason Hoth J, Hiltbold EM. Type I interferon signaling regulates the composition of inflammatory infiltrates upon infection with Listeria monocytogenes. Cell Immunol 2011; 273:41-51.
41. Patel AA, Lee-Lewis H, Hughes-Hanks J, Lewis CA, Anderson DM. Opposing roles for interferon regulatory factor-3 (IRF-3) and type I interferon signaling during Plague. PLoS Pathog 2012; 8:e1002817.
42. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect Immun 1997; 65:3847-51.
43. Pinheiro da Silva F, Soriano FG. Neutrophils recruitment during sepsis: critical points and crossroads. Front Biosci 2009; 14:4464-76.
44. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009; 119:1910-20.
45. Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM. Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol 2007; 82:1353-60.
46. Litvak V, Ratushny AV, Lampano AE, et al. A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 2012; 490:421-5.
47. Broos S, Hulpiau P, Galle J, Hooghe B, Van Roy F, De Bleser P. ConTra v2: a tool to identify transcription factor binding sites across species, update 2011. Nucleic Acids Res 2011; 39:W74-8.
48. Nozell S, Laver T, Patel K, Benveniste EN. Mechanism of IFN-betamediated inhibition of IL-8 gene expression in astroglioma cells. J Immunol 2006; 177:822-30.
49. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53.